{"product_id":"biogen-pestle-analysis","title":"Biogen PESTLE Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMake Smarter Strategic Decisions with a Complete PESTEL View\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eNavigate the complex external landscape shaping Biogen—from tightening pharma regulations to rapid biotech innovation—and turn those insights into strategic advantage.\u003c\/p\u003e\n\u003cp\u003eOur concise PESTLE highlights key political, economic, social, technological, legal, and environmental forces affecting Biogen; purchase the full analysis for the complete, actionable breakdown ready for investment, strategy, or pitch use.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eolitical factors\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInflation Reduction Act price negotiations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe Inflation Reduction Act’s Medicare negotiation program forces Biogen to recalibrate pricing for top biologics; CMS-selected drugs could face average price cuts of 15–25%, directly impacting blockbuster neurology revenues like those from Aduhelm and Tysabri.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFDA regulatory pathways for neurology\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe FDA has increasingly favored accelerated pathways for neurodegenerative unmet needs, exemplified by the 2021 accelerated approval of aducanumab and rising use of surrogate endpoints; Biogen benefits from faster market access but faces political pressure to deliver post‑marketing evidence—FDA required confirmatory trials and Biogen pledged additional studies after 2021; policymakers monitor fast‑track approvals closely given Alzheimer’s affects ~6.7 million US adults (2024 est.) and urgent ALS needs.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInternational trade and supply chain policy\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eGeopolitical tensions and US-China trade policies disrupt Biogen’s global supply chain, with 18% of active pharmaceutical ingredient sourcing exposed to China\/Taiwan as of 2024, raising logistics costs by an estimated 5–8% in 2024–25.\u003c\/p\u003e\n\u003cp\u003ePolitical initiatives to reshore biotech manufacturing—supported by US CHIPS and Science Act funding and EU strategic autonomy plans—have prompted Biogen to evaluate investments in North American and European facilities, targeting CAPEX increases of roughly $200–400m through 2026.\u003c\/p\u003e\n\u003cp\u003eTariffs and export controls on specialized lab equipment and raw materials vary with diplomatic relations; a 10–25% tariff scenario could raise production input costs materially and extend lead times, affecting margins on high-margin neurology biologics.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGovernment R\u0026amp;D funding and grants\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eFederal NIH funding, which totaled about $48.3 billion in FY2024, underpins early-stage neurological research that fuels Biogen’s pipeline and de-risks discovery efforts.\u003c\/p\u003e\n\u003cp\u003eCongressional budget choices directly affect the volume of foundational science Biogen can translate; a 1–2% NIH funding shift alters grant availability for key programs in neuroscience.\u003c\/p\u003e\n\u003cp\u003ePolitical shifts can reprioritize areas—boosting rare genetic disorder funding (e.g., increased ARPA-H\/NIH initiatives) or diverting resources elsewhere, changing the future target landscape for Biogen.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eNIH FY2024 budget: $48.3B\u003c\/li\u003e\n\u003cli\u003eSmall % shifts (1–2%) materially affect grant pools\u003c\/li\u003e\n\u003cli\u003ePolicy changes can favor or deprioritize rare genetic disorder research\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal healthcare reform initiatives\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eGlobal shifts toward universal healthcare and centralized procurement in Europe and Asia compress Biogen’s international margins; EU tendering and China’s bulk-buy programs have driven price cuts up to 40% in some categories. \u003c\/p\u003e\n\u003cp\u003eBy late 2025, stricter cost-containment measures across multiple markets target orphan-drug premiums, risking revenue on high-margin neurology products that contributed over $6.5bn of Biogen’s 2024 revenue. \u003c\/p\u003e\n\u003cp\u003eBiogen must engage health ministries and negotiate outcomes-based contracts and managed-entry agreements to preserve access and pricing for innovative therapies. \u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eCentralized procurement and universal-care policies reduce prices up to ~40%\u003c\/li\u003e\n\u003cli\u003eOrphan-drug pricing under pressure in 2025 across Europe\/Asia\u003c\/li\u003e\n\u003cli\u003eNeurology portfolio ~$6.5bn of 2024 revenue at risk\u003c\/li\u003e\n\u003cli\u003eProactive ministry engagement and outcomes-based contracts essential\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMedicare cuts, China API risk and NIH funding shift threaten biologics margins\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eMedicare negotiation under IRA could cut selected biologic prices 15–25%, threatening neurology revenue; FDA accelerated approvals boost access but require confirmatory trials; 18% API exposure to China\/Taiwan raises supply risk and ~5–8% logistics cost pressure; NIH FY2024 $48.3B supports pipeline but 1–2% shifts affect grant flow.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eMedicare price cut\u003c\/td\u003e\n\u003ctd\u003e15–25%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAPI exposure\u003c\/td\u003e\n\u003ctd\u003e18%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLogistics cost rise\u003c\/td\u003e\n\u003ctd\u003e5–8%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNIH FY2024\u003c\/td\u003e\n\u003ctd\u003e$48.3B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eExplores how external macro-environmental factors uniquely affect Biogen across six dimensions—Political, Economic, Social, Technological, Environmental, and Legal—each section backed by current data and trends to identify threats and opportunities for executives, investors, and strategists.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eA concise, visually segmented Biogen PESTLE summary that eases review during meetings, supports quick alignment across teams, and can be dropped into presentations or notes for streamlined external risk and market positioning discussions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eE\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003economic factors\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBiosimilar market competition\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cpthe biosimilar influx in ms has cut biogen legacy-revenue by roughly key markets with natalizumab and other older biologics losing rapid share as patents lapse.\u003e\u003cpfaced with biosimilars priced lower biogen is accelerating a shift toward high-margin next biologics and gene therapies to replace declining cash flows.\u003e\u003cpthis dynamic forces tight cost-structure optimization prioritization and manufacturing efficiency protect margins amid projected revenue headwinds through\u003e\n\u003c\/pthis\u003e\u003c\/pfaced\u003e\u003c\/pthe\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCost of capital and interest rates\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eHigh interest rates in the mid-2020s pushed US benchmark rates to ~5% by 2024–2025, raising Biogen’s weighted average cost of capital and increasing financing costs for large R\u0026amp;D and M\u0026amp;A; the company reported net debt of about $3.8bn in FY2024, heightening sensitivity to rate moves. Biogen must manage its debt profile and prioritize capital allocation to sustain growth under restrictive monetary policy. Investors demand disciplined spending and clearer paths to profitability for late-stage assets, especially given R\u0026amp;D spend of roughly $2.1bn in 2024. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCurrency exchange rate volatility\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAs a global entity, Biogen is highly exposed to USD fluctuations versus EUR, JPY and other currencies; in 2024 FX movements swung reported international revenues by about 3–5%, and similar volatility persisted into 2025. Currency swings in 2025 can produce significant quarter-to-quarter changes in reported international earnings, complicating multi-year guidance and capital allocation. Biogen uses hedging—forward contracts and options—to reduce short-term translation risk, though sustained macro shifts like a 10% USD appreciation would still materially impact EBITDA. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eValue-based healthcare pricing models\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eThe shift to value-based care requires Biogen to tie Alzheimer’s drug pricing to measurable outcomes and long-term system savings; payers now seek proof that high-cost therapies cut hospitalizations and long-term care costs, with outcomes-based contracts rising—by 2024 about 20–30% of US commercial plans pursued such arrangements for specialty drugs.\u003c\/p\u003e\n\u003cp\u003eBiogen must therefore invest heavily in health economics and outcomes research (HEOR); analysts estimate Biogen’s HEOR and evidence-generation costs could rise into the low hundreds of millions annually to support real-world effectiveness and justify premium pricing for treatments reducing total care costs.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eValue-based pricing link to patient outcomes and system savings\u003c\/li\u003e\n\u003cli\u003ePayer demand: reduce hospital\/long-term care burden; 20–30% commercial uptake (2024)\u003c\/li\u003e\n\u003cli\u003eIncreased HEOR spend—potentially hundreds of millions yearly to validate outcomes\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal inflationary pressures\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cpsustained inflation in labor specialized chemicals and energy has raised biogen cogs sg with costs up yoy specialty chemical prices pressuring margins.\u003e\n\u003cpbiogen retains pricing power for niche neurologic biologics but cannot fully pass cost increases to payers limiting revenue offset and squeezing operating margins.\u003e\n\u003cpmanaging inflation across a global supply chain cost controls supplier renegotiations and efficiency initiatives central to protecting operating margins through\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eEnergy costs +12% YoY (2024)\u003c\/li\u003e\n\u003cli\u003eSpecialty chemical prices +9% (2024)\u003c\/li\u003e\n\u003cli\u003eFocus: cost controls, supplier renegotiation, efficiency gains\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/pmanaging\u003e\u003c\/pbiogen\u003e\u003c\/psustained\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBiosimilars slash MS revenue 30–40%; $2.1bn R\u0026amp;D, $3.8bn debt squeeze margins\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cpbiosimilar pressure cut legacy ms revenue r spend and net debt raise financing sensitivity amid us rates. fx moves altered reported intl energy specialty chemicals hurt cogs heor costs may rise to low hundreds of millions support value-based pricing.\u003e\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eBiosimilar impact\u003c\/td\u003e\n\u003ctd\u003e-30%–40%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D\u003c\/td\u003e\n\u003ctd\u003e$2.1bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet debt\u003c\/td\u003e\n\u003ctd\u003e$3.8bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFX revenue swing\u003c\/td\u003e\n\u003ctd\u003e3%–5%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEnergy costs\u003c\/td\u003e\n\u003ctd\u003e+12%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eChemicals\u003c\/td\u003e\n\u003ctd\u003e+9%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/pbiosimilar\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eFull Version Awaits\u003c\/span\u003e\u003cbr\u003eBiogen PESTLE Analysis\u003c\/h2\u003e\n\u003cp\u003eThe preview shown here is the exact Biogen PESTLE Analysis document you’ll receive after purchase—fully formatted and ready to use.\u003c\/p\u003e\n\u003cp\u003eNo placeholders or teasers: the content, layout, and structure visible here are the final file you’ll be able to download immediately after payment.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56751416213881,"sku":"biogen-pestle-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/biogen-pestle-analysis.png?v=1772231121","url":"https:\/\/matrixbcg.com\/products\/biogen-pestle-analysis","provider":"MatrixBCG","version":"1.0","type":"link"}